At a glance
ClinicalIndex Comparison RecordPhase 2Active· 3 enrolled
Drug / intervention
MBG-453 + Azacitidinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial
In Brief
A Phase 2 clinical trial evaluating MBG-453 + Azacitidine for AML. Active but no longer recruiting, targeting 3 participants across 1 site.
Detailed Summary
To demonstrate the efficacy of targeted and tailored sequential therapy in patients with AML.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAML
CountriesUnited States
CollaboratorsAustralasian Leukaemia and Lymphoma Group
Timeline
Phase 2Active
2025202620272028
First PostedOct 2024
Enrollment StartDec 2024
TodayJul 2026
Primary CompletionJul 2026
Study CompletionJul 2028
First PostedOct 30, 2024
Enrollment StartDec 30, 2024
Primary CompletionJul 31, 2026
Study CompletionJul 31, 2028
TodayJul 1, 2026
Enrollment to primary: 1.6 yearsPosted 1.7 years agoPrimary completion in 1 month
Interventions
MBG-453 + Azacitidinedrug
Given intravenously (by vein)